Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloperidone Titration Safety Study in Bipolar I or Schizophrenia
NCT04127058Phase 1Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Oct 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of iloperidone in bipolar I disorder and schizophrenia (2 arms), sponsored by Vanda Pharmaceuticals Inc. Primary endpoint: Frequency of treatment-emergent adverse events at 7 days. Started Oct 2019; status: completed.
02
Drugs
iloperidone
03
Conditions
bipolar I disorderschizophrenia
Beyond the preview
Go deeper on NCT04127058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04127058.